
NanoTalks
- Miguel Ángel Esteve
- 19/12/2025
Polymer Drug Conjugates Explained
Explore how polymer–drug conjugates (PDCs) are transforming targeted drug delivery by improving solubility, extending circulation time, and enabling controlled, site-specific release of therapeutic payloads.
This article explores the evolution of PDCs from early PEGylated systems to next-generation platforms based on PEG alternatives, anionic polyelectrolytes such as poly(glutamic acid) (PGA), and polypeptide-based polymers, highlighting their clinical relevance, GMP readiness, and role in advancing modern small-molecule and biologic therapies.
Recent Articles
- Miguel Ángel Esteve
- December 18, 2025
- Miguel Ángel Esteve
- November 13, 2025
- Miguel Ángel Esteve
- October 15, 2025
- Miguel Ángel Esteve
- September 11, 2025
- Miguel Ángel Esteve
- July 30, 2025
- Miguel Ángel Esteve
- July 2, 2025
- Miguel Ángel Esteve
- June 9, 2025
- Miguel Ángel Esteve
- May 19, 2025
- Miguel Ángel Esteve
- April 29, 2025
- Elena Gallon
- April 8, 2025
- Samuel García
- March 20, 2025
- Miguel Ángel Esteve
- March 11, 2025
- Miguel Ángel Esteve
- March 4, 2025
- Miguel Ángel Esteve
- February 10, 2025
- Miguel Ángel Esteve
- February 10, 2025
Sign Up for NanoTalks
Subscribe to NanoTalks, the magazine of Curapath. Stay up to date on the latest developments, trends and news in the world of non-viral vectors, plus discover the latest advances in nanobiotechnology.
